We disclose an in-toilet urinalysis system which includes a system for collection urine and for analysis of urine components using aptamer technology. Urine collection system may dispense urine into cuvettes, channels, or other containers that include aptamers. The aptamers may detect target molecules in urine. The aptamers may measure urine analytes, detect excreted drugs or drug metabolites, or disease markers. Upon binding to the target molecule, the aptamers may produce a signal which a sensor in the toilet may detect. In some embodiments, the signal may be electrochemical, fluorescent, or colorimetric. The measurements obtained from analysis of the urine may be used to assess a user's health or diagnose disease. In some embodiments, the measurements are stored in a controller which may transmit the measurements to a healthcare provider for assessment.

A method for training a baseline risk model, including: pre-processing input data by normalizing continuous variable inputs and producing one-hot input features for categorical variables; providing definitions for clean input data and dirty input data based upon various input data related to a patient condition; segmenting the input data into clean input data and dirty input data, wherein the clean input data includes a first subset and a second subset, where the first subset and the second subset include all of the clean input data and are disjoint; training a machine learning model using the first subset of the clean data; and evaluating the performance of the trained machine learning model using the second subset of the clean input data and the dirty input data.

Fluorescence imaging with reduced fixed pattern noise is disclosed. A method includes actuating an emitter to emit a plurality of pulses of electromagnetic radiation and sensing reflected electromagnetic radiation resulting from the plurality of pulses of electromagnetic radiation with a pixel array of an image sensor to generate a plurality of exposure frames. The method includes applying edge enhancement to edges within an exposure frame of the plurality of exposure frames. The method is such that at least a portion of the plurality of pulses of electromagnetic radiation emitted by the emitter comprises one or more of electromagnetic radiation having a wavelength from about 795 nm to about 815 nm.

Fluorescence imaging with reduced fixed pattern noise is disclosed. A method includes actuating an emitter to emit a plurality of pulses of electromagnetic radiation and sensing reflected electromagnetic radiation resulting from the plurality of pulses of electromagnetic radiation with a pixel array of an image sensor to generate a plurality of exposure frames. The method includes applying edge enhancement to edges within an exposure frame of the plurality of exposure frames. The method is such that at least a portion of the plurality of pulses of electromagnetic radiation emitted by the emitter comprises one or more of electromagnetic radiation having a wavelength from about 795 nm to about 815 nm.

Urine collection systems and associated methods and devices are disclosed herein. A representative system can include a urine collection device, a flow control assembly configured to direct a urine flow from the patient to the urine collection device, and a urine measurement device including a first sensor and a second sensor. The first sensor is configured to generate first sensor data based on a weight of the container, and the second sensor is configured to generate second sensor data based on the urine flow from the patient to the container. The system can further include non-transitory computer readable media having instructions that, when executed by one or more processors, cause the system to perform operations comprising determining a first patient urine output based on the first sensor data; and determining a second patient urine output based on the second sensor data.

The present disclosure relates generally to using detected bladder events for the diagnosis of urinary incontinence or the treatment of lower urinary tract dysfunction. A system includes a sensing device comprising a pressure sensor to directly detect a pressure within a bladder. The sensing device is adapted to be located within the bladder. The system also includes a signal processing device to: receive a signal indicating the detected pressure within the bladder; detect a bladder event based the detected pressure within the signal; and characterize the bladder event as a bladder contraction event or a non-contraction event. The characterization of the bladder event can be used in the diagnosis of urinary incontinence or the treatment of lower urinary tract dysfunction.

A urine analysis device includes a case configured to be positioned entirely within a toilet, the case having a front face for receiving a stream of urine directly from a user urinating on the toilet a rear face opposite the front face, and a collection port, disposed on either the front face or the rear face, wherein the case contains a test assembly configured to perform an analysis on urine collected through the collection port.

In one example in accordance with the present disclosure, an electronic device is described. The example electronic device includes a microphone device to record a tracheal sound. The example electronic device also includes an oral expiratory flow sensor to measure oral expiratory flow contents. The example electronic device further includes a processor to determine a health condition based on the tracheal sound and the oral expiratory flow contents.

A measurement chamber that is essentially dome shaped and has a base area with a membrane and has at least two connection points fora fluid flow. The measurement chamber has two outer webs opposite each other, one of the webs engaging a clamping edge of a coupling element.

Systems, methods, and computer-readable media are provided for identification of patients having an elevated near-term risk of chronic kidney disease progression, including quantitatively predicting whether or not an elevated risk of progression of Stage 3 or Stage 4 chronic kidney disease is likely within a time interval of up to 36 months subsequent to computing the prediction. Based on the prediction, appropriate care providers may be notified so that the risk of CKD progression may be mitigated. In some embodiments, serial measurements are obtained of urine osmolality, and a challenge with an AVP V2 antagonist and serum sodium concentration is provided. From a time series based on the serial measurements, estimates of each variable's velocity and/or doubling-time may be determined. These values then may be combined via a multivariable mathematical model for providing a leading indicator of near-term future abnormalities in kidney function.